12.88 USD
+0.35 (+2.79%)
13.5799 USD
+0.7 (+5.43%)
ChartMill assigns a Buy % Consensus number of 87% to BBOT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.48. This target is 90.06% above the current price.
BBOT was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about BBOT.
In the previous month the buy percentage consensus was at a similar level.
BBOT was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-05 | Morgan Stanley | Initiate | Overweight |
| 2025-11-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-11-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-17 | Leerink Partners | Initiate | Outperform |
| 2025-09-15 | HC Wainwright & Co. | Initiate | Buy |
| 2025-09-04 | Oppenheimer | Initiate | Outperform |
| 2025-08-18 | Wedbush | Initiate | Outperform |
BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ
What is the price target for BBOT stock?
12 analysts have analysed BBOT and the average price target is 24.48 USD. This implies a price increase of 90.06% is expected in the next year compared to the current price of 12.88.
How do analysts rate BRIDGEBIO ONCOLOGY THERAPEUT (BBOT)?
The consensus rating for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.